A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer

Lung Cancer（2021）

引用 29|浏览16

暂无评分

摘要

•Osimertinib 80 mg showed limited efficacy for NSCLC with EGFR ex20ins mutations.•The mutation type-specific concentration-dependency of osimertinibwas highlighted.•This study proposes higher dose osimertinib for NSCLC with EGFR ex20ins mutations.

查看译文

关键词

EGFR ex20ins,NSCLC,PFS,AUC

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要